Type 2 Diabetes (Combine 1)

Diabetes mellitus is a metabolic disorder characterized by the presence of hyperglycemia due to defective insulin secretion, insulin action or both.  There is an unmet medical need for people with Type 2 Diabetes for products with the potential to improve clinical outcomes through reduced treatment burden, such as fewer injections and increased treatment adherence compared to other treatment regimens requiring daily or several weekly injections.

This study will compare the new investigational medicine IcoSema, which is a combination of

insulin icodec and semaglutide, taken once a week, to insulin icodec taken once a week.  The

study will look at how well IcoSema controls blood sugar level when compared to insulin icodec. 

The study will last a little over one year. 

A few qualifications to participate are: 

• Male or female above or equal to 18 years of age 
• Diagnosed with type 2 diabetes mellitus ≥ 180 days before screening 
• Treated with once-daily or twice-daily basal insulin (neutral protamine hagedorn insulin, insulin degludec, insulin detemir, insulin glargine 100 units/mL, or insulin glargine 300 units/mL) 20-80 units/day ≥ 90 days before screening